依折麦布联合瑞舒伐他汀钙对冠心病合并高胆固醇血症患者心血管不良事件的影响

Effect of ezetimibe combined with rosuvastatin calcium on adverse cardiovascular events in patients with coronary heart disease and hypercholesterolemia

目的探讨依折麦布联合瑞舒伐他汀钙对冠心病合并高胆固醇血症患者心血管不良事件的影响。方法 80例冠心病合并高胆固醇血症患者,按照随机数字表法分为观察组与对照组,各40例。在常规治疗基础上,对照组单用瑞舒伐他汀钙治疗,观察组采用依折麦布联合瑞舒伐他汀钙治疗。观察比较两组的治疗效果。结果治疗后,两组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平较治疗前降低,高密度脂蛋白胆固醇(HDL-C)水平较治疗前升高,差异均有统计学意义(P<0.05)。治疗后,观察组TC、LDL-C、HDL-C水平分别为(4.35±0.74)、(2.33±0.46)、(1.62±0.51)mmol/L,优于对照组的(5.02±0.85)、(2.89±0.55)、(1.35±0.45)mmol/L,差异均有统计学意义(P<0.05)。治疗后1、3个月两组急性冠状动脉综合征、心源性卒死、脑梗死心发生率比较差异无统计学意义(P>0.05)。治疗后6个月、1年及2年,观察组急性冠状动脉综合征与脑梗死发生率明显低于对照组,差异有统计学意义(P<0.05);两组心源性猝死发生率比较差异无统计学意义(P>0.05)。结论对冠心病合并高胆固醇血症患者使用依折麦布联合瑞舒伐他汀钙治疗临床效果显著,且可降低心血管不良事件发生率,值得临床推广。

Objective To discuss the effect of ezetimibe combined with rosuvastatin calcium on adverse cardiovascular events in patients with coronary heart disease and hypercholesterolemia. Methods A total of 80 patients with coronary heart disease and hypercholesterolemia were divided into observation group and control group by random number table method, with 40 cases in each group. On the basis of conventional therapy, the control group was treated with rosuvastatin calcium only, and the observation group was treated with ezetimibe and rosuvastatin calcium. The therapeutic effect in the two groups was observed and compared. Results After treatment, the levels of total cholesterol(TC) and low density lipoprotein cholesterol(LDL-C) in the two groups was lower than those before treatment, and high density lipoprotein cholesterol(HDL-C) was higher than those before treatment. Their difference was statistically significant(P<0.05). After treatment, the levels of TC, LDL-C and HDL-C were(4.35±0.74),(2.33±0.46) and(1.62±0.51) mmol/L respectively in the observation group, which was better than(5.02±0.85),(2.89±0.55) and(1.35±0.45) mmol/L in the control group, and their difference was statistically significant(P<0.05). After 1 and 3 months of treatment, there was no statistically significant difference in incidence of acute coronary syndrome, sudden cardiac death, cerebral infarction between the two groups(P>0.05).After 6 months, 1 year and 2 years of treatment, the incidence of acute coronary syndrome, cerebral infarction was obviously lower than those in the control group, and their difference was statistically significant(P<0.05). There was no statistically significant difference in incidence of sudden cardiac death between the two groups(P>0.05). Conclusion Ezetimibe combined with rosuvastatin calcium shows remarkable clinical effect on patients with coronary heart disease and hypercholesterolemia, and it can reduce the incidence of adverse cardiovascular events, which is worthy of clinical promotion.